Qiuyan Jiang
Nankai University
11 Papers
17 Citations
Qiuyan Jiang is an academic researcher from Nankai University. The author has contributed to research in topics: Pulmonary fibrosis & Myofibroblast. The author has an hindex of 2, co-authored 11 publications.
Chat about Author
Papers
Betulinic acid attenuated bleomycin-induced pulmonary fibrosis by effectively intervening Wnt/β-catenin signaling.
Xiaohe Li,Xiaowei Liu,Deng Ruxia,Shaoyan Gao,Qiuyan Jiang,Liu Rui,Hailong Li,Yang Miao,Yunqian Zhai,Shanshan Zhang,Zhenzhen Wang,Yimeng Ren,Wen Ning,Honggang Zhou,Cheng Yang +14 more
TL;DR: BA may directly interfere with the Wnt/β-catenin pathway to subsequently repress myofibroblast activation and pulmonary fibrosis.
23
Nintedanib Inhibits Wnt3a-Induced Myofibroblast Activation by Suppressing the Src/β-Catenin Pathway.
Xiaohe Li,Xiaowei Liu,Deng Ruxia,Shaoyan Gao,Yu Haiyan,Kai Huang,Qiuyan Jiang,Liu Rui,Xiaoping Li,Liang Zhang,Honggang Zhou,Cheng Yang +11 more
TL;DR: This study found that nintedanib attenuated myofibroblast activation through inhibiting the expression of genes downstream of Wnt signaling such as Cyclin D1, Wisp1, and S100a4 and exhibits an anti-fibrosis effect.
Deglycosylated Azithromycin Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-β1 Signaling Pathway
Hao Ruan,Shaoyan Gao,Shuangling Li,Jiaoyan Luan,Qiuyan Jiang,Xiaohe Li,Huijun Yin,Honggang Zhou,Cheng Yang +8 more
TL;DR: Zhang et al. as discussed by the authors showed that Deg-AZM exerts antifibrotic effects by inhibiting TGF-β1-induced myofibroblast activation and EMT.
6
Patent
Application of bergenin in preparing medicaments for treating pulmonary fibrosis diseases
Honggang Zhou,Cheng Yang,Li Lixin,Li Huiying,Hong Kang,Liu Yang,Xiaohe Li,Qi Min,Qiuyan Jiang,Shao Shuaibo,Shaoyan Gao,Cui Yunyao,Liu Rui,Wang Yanhua +13 more
- 07 May 2019
TL;DR: The bergenin has good efficacy on pulmonary fibrosis, has no adverse reaction, can slow down bleomycin-induced pneumothorax-induced lung fibrosis in mice, and has good application prospect in the aspect of treating, relieving, or improving pulmonary diseases as mentioned in this paper.
1
Patent
Application of myricetin for preparing medicine for treating pulmonary fibrosis disease
Zhou Honggang,Yang Cheng,Wei Yang,Li Lixin,Li Huiying,Sun Ruiqiu,Gao Jingjing,Li Xiaohe,Qi Min,Huang Kai,Shaoyan Gao,Qiuyan Jiang,Ma Ling,Liu Rui,Wang Yanhua +14 more
- 17 May 2019
TL;DR: In this article, the structural formula of myricetin has been used for the treatment of pulmonary fibrosis in mice, no adverse reaction was generated, and mouse pulmonary Fibrosis induced by bleomycin can be slowed down.